ImageneBio Inc
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ImageneBio Inc (NASDAQ:IMA) is a clinical-stage biotechnology company that develops therapeutics for immunological, autoimmune and inflammatory diseases. The company offers IMG-007, a next-generation non-depleting anti-OX40 monoclonal antibody with extended half-life designed to inhibit OX40 receptor signaling without T-cell depletion for enhanced efficacy, safety and patient convenience; IMG-007 has completed Phase 2a clinical trials in atopic dermatitis and alopecia areata and advances in a Phase 2b trial for moderate-to-severe atopic dermatitis. Founded in 2019 and headquartered at 12526 High Bluff Drive, Suite 345, San Diego, California, ImageneBio targets patients with immunology and inflammation disorders worldwide through its differentiated pipeline. In July 2025, the company completed a reverse merger with Inmagene Biopharmaceuticals, formerly operating as Ikena Oncology Inc, and concurrently raised $75 million in private placement financing from investors including Deep Track Capital, Foresite Capital and RTW Investments; the combined entity now trades under the IMA ticker and strengthened its management team while continuing IMG-007 development.
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
ImageneBio $30 Million Private Placement Ignites Stock
ImageneBio Announces $30 Million Private Placement
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
ImageneBio to Participate in Leerink Global Healthcare Conference
BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team
ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences
ImageneBio, Inc. (NASDAQ:IMA) Short Interest Update
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade